Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?

CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment. To date, there is no predictive test for therapeutic response after injection of CAR-T cells. Recent studies have shown that the level of trogocytosis by immune cells correlates with the persistence of tumor cells in patients with hematological malignancies. Our main objective is to identify a phenotypic "signature" of trogocytosis predictive of therapeutic response 6 months after in

Trial Details

NCT ID
NCT06352242
Phase
NA
Sponsor
University Hospital, Montpellier
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients
  • Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers
Locations (sample)
  • Montpellier, France|43.61093,3.87635
  • Montpellier, France|43.61093,3.87635

Key Eligibility Criteria

  • For patients
  • Patient who has given free and informed consent in writing for inclusion in the non-interventional CART-BANK protocol, and orally for the CARTROG p…
  • Patients over 18 years of age at the time of inclusion,
  • Diagnosis of LDGCB,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →